It is thus feasible that signaling pathways such as the EGFR or ERK pathways, which integrate the signaling from second messenger systems to target genes, may offer a better therapeutic target to reverse the adverse effects of prostanoid signaling, or indeed signaling in response to multiple prostanoids, in cancer. The gene discussed is EGFR; the disease is cancer.